Pfizer Inventory 2010-2024 | PFE

Pfizer inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • Pfizer inventory for the quarter ending September 30, 2024 was $11.447B, a 11.03% increase year-over-year.
  • Pfizer inventory for 2023 was $10.189B, a 13.45% increase from 2022.
  • Pfizer inventory for 2022 was $8.981B, a 0.86% decline from 2021.
  • Pfizer inventory for 2021 was $9.059B, a 12.96% increase from 2020.
Pfizer Annual Inventory
(Millions of US $)
2023 $10,189
2022 $8,981
2021 $9,059
2020 $8,020
2019 $7,068
2018 $7,508
2017 $7,578
2016 $6,783
2015 $7,513
2014 $5,663
2013 $6,166
2012 $6,076
2011 $6,610
2010 $8,275
2009 $12,403
Pfizer Quarterly Inventory
(Millions of US $)
2024-06-30 $11,447
2024-03-31 $10,892
2023-12-31 $10,189
2023-09-30 $10,204
2023-06-30 $10,310
2023-03-31 $9,541
2022-12-31 $8,981
2022-09-30 $9,513
2022-06-30 $10,454
2022-03-31 $9,979
2021-12-31 $9,059
2021-09-30 $8,640
2021-06-30 $8,948
2021-03-31 $8,493
2020-12-31 $8,020
2020-09-30 $9,295
2020-06-30 $8,564
2020-03-31 $8,423
2019-12-31 $7,068
2019-09-30 $8,222
2019-06-30 $8,233
2019-03-31 $8,029
2018-12-31 $7,508
2018-09-30 $8,184
2018-06-30 $8,074
2018-03-31 $8,148
2017-12-31 $7,578
2017-09-30 $7,925
2017-06-30 $7,584
2017-03-31 $7,415
2016-12-31 $6,783
2016-09-30 $7,507
2016-06-30 $7,614
2016-03-31 $7,578
2015-12-31 $7,513
2015-09-30 $7,678
2015-06-30 $5,796
2015-03-31 $5,786
2014-12-31 $5,663
2014-09-30 $6,355
2014-06-30 $6,249
2014-03-31 $6,066
2013-12-31 $6,166
2013-09-30 $6,482
2013-06-30 $6,282
2013-03-31 $7,035
2012-12-31 $6,076
2012-09-30 $7,516
2012-06-30 $7,001
2012-03-31 $7,189
2011-12-31 $6,610
2011-09-30 $8,426
2011-06-30 $8,597
2011-03-31 $8,467
2010-12-31 $8,275
2010-09-30 $8,771
2010-06-30 $9,511
2010-03-31 $10,132
2009-12-31 $12,403
2009-09-30 $5,058
2009-06-30 $4,993
2009-03-31 $4,458
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $151.422B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51